India’s pharmaceutical exports are set to double to reach US$ 65 billion by 2030, driven by strategic moves into complex generics, advanced therapies, and global expansion, reveals a recent report by Rubix Data Sciences. Despite US tariff threats and heavy reliance on China for bulk drugs, Indian pharma is improving regulatory compliance and seizing opportunities from upcoming patent expirations. Pharma exports rose 9.3% in FY25, reaching US$ 30.5 billion. The sector shows resilience amid global trade uncertainties.
India’s pharmaceutical exports have the potential to double to US$ 65 billion by 2030, despite facing US tariff threats and regulatory challenges, according to Rubix Data Sciences report. This projected growth is driven by strategic initiatives such as a strong push into advanced therapeutic areas and increased focus on complex generics.
Rubix Data Sciences, a leading risk management and monitoring firm, recently released a new report on India’s pharmaceutical industry. The report highlights how Indian pharma companies are responding to global uncertainties by intensifying their focus on complex generics, broadening their international footprint, and strengthening regulatory compliance.
The report noted that Indian drug makers are increasingly pursuing strategic acquisitions in the US and Europe, particularly through contract development and manufacturing organisations (CDMOs), to strengthen their global footprint and offset external risks.
The US remains India’s largest pharmaceutical export destination, accounting for 32% of total shipments. However, the US President Donald Trump’s recent proposal to impose a steep 200% tariff on pharma imports poses a significant challenge.
In response, Indian companies are diversifying their offerings and moving into specialised therapeutic segments such as oncology, anti-diabetics, and treatments for the central nervous system. These efforts could help India climb into the top five global pharma exporters by 2047, especially through innovations in biosimilars, specialty generics, and novel drug formulations.
Adding to the sector’s growth potential is the anticipated expiration of patents on small-molecule drugs worth US$ 63.7 billion between 2025 and 2029. This upcoming wave of expirations presents a timely opportunity for Indian pharmaceutical companies to expand their generics portfolio. Firms with expanding US operations and experience in complex generics, such as Cipla and Lupin, are well-positioned to benefit. Even companies with a smaller US presence, like Alembic Pharmaceuticals and Shilpa Medicare, stand to gain due to their investments in differentiated products including injectables and respiratory therapies.
The Rubix’s findings indicate that India’s pharmaceutical industry has significantly improved its compliance with international regulations. The number of manufacturing facilities receiving the US FDA’s Official Action Indicated (OAI) status has dropped to 11%—a sharp decline from 23% in 2014—even as the global OAI rate rose to 14% in 2024. This improvement underscores the sector’s efforts to enhance quality standards and regulatory alignment.
In financial year 2024–25, Indian pharmaceutical exports reached US$ 30.5 billion, marking a 9.3% surge from the previous year.
According to the Pharmaceuticals Export Promotion Council of India (Pharmexcil), India’s pharmaceutical exports remained robust at US$ 4.9 billion in April-May FY26. Formulations and biologics accounted for a significant 75.74% of overall pharmaceutical exports, while bulk drugs and drug intermediates registered a 4.40% growth in May. Vaccine exports rose by 13.64%, reaching US$ 190.13 million, while surgical products grew by 8.58% and Ayush and herbal products by 7.36%, reflecting strong overall growth.
The Pharmexcil reported that approximately 76% of India’s pharmaceutical exports are directed to key markets, including the NAFTA region, Europe, Africa, and Latin America.
The strong growth in pharmaceutical exports is a positive indicator of how Indian manufacturers are adjusting to global headwinds. Whether it is navigating tariff challenges, improving regulatory standards, or expanding internationally, the sector is clearly evolving with strategic focus.
However, with 74% of India’s bulk drug imports still coming from China, the report emphasizes the critical need to diversify both supply sources and customer markets to strengthen long-term resilience.
Amid rising politicization of global supply chains and growing protectionist measures that threaten access to affordable medicines, this report arrives at a crucial moment. As the August 1 tariff deadline approaches, the decisions made by Indian policymakers and industry leaders could have far-reaching implications—not only for India’s growth but also for the health of millions around the world who rely on Indian pharmaceuticals.
